Use your antibodies-online credentials, if available.
F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. 再加上，我们可以发Factor VIII 抗体 (338) 和 Factor VIII 蛋白 (22)和数多这个蛋白质的别的产品。
Showing 10 out of 58 products:
Human Factor VIII ELISA Kit for Sandwich ELISA - ABIN456987
Wang, Yuan, Zhong, Wen, Deng, Liang, Zheng: The anticoagulant effect of PGI2S and tPA in transgenic umbilical vein endothelial cells is linked to up-regulation of PKA and PKC. in International journal of molecular sciences 2014
Show all 2 Pubmed References
gene is flanked by factor VII (显示 TH ELISA试剂盒) and factor X genes; gene encodes a protein homologous to factor VII (显示 TH ELISA试剂盒), but lacks critical residues for factor VII (显示 TH ELISA试剂盒) activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas
Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days.
results revealed localized vascular expression of FVIII and von Willebrand factor (显示 VWF ELISA试剂盒) and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues.
the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor (显示 VWF ELISA试剂盒) masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.
data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice
Both platelet-VWF (显示 VWF ELISA试剂盒) and plasma-VWF (显示 VWF ELISA试剂盒) are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.
These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.
Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.
This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 (显示 LRP1 ELISA试剂盒) cluster III.
a fragment containing only approximately 20% of the VWF (显示 VWF ELISA试剂盒) sequence is sufficient to support FVIII stability in vivo
Endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.
Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor (显示 VWF ELISA试剂盒) and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.
Each hFVIII vector was administered to FVIII knockout (KO) mice at a dose of 10(10) genome copies (GC) per mouse. Criteria for distinguishing the performance of the different enhancer/promoter combinations were established prior to the initiation of the studies.
Relevance of ethnic differences in factor XIII (显示 UGDH ELISA试剂盒) activity on laboratory reference ranges.
analysis of co-existing variants in both F8 and PTGS-1 (显示 PTGS1 ELISA试剂盒) genes in a three-generation pedigree of hemophilia A
FVIII endocytosis is driven by interaction with LRP1 (显示 LRP1 ELISA试剂盒)
A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa (显示 F10 ELISA试剂盒) complex activates FVIII apart from thrombin (显示 F2 ELISA试剂盒) feedback.
An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII by thrombin (显示 F2 ELISA试剂盒) has been presented.
Of special importance is the sequential formation of disulfide bonds with different functions in structural support of VWF (显示 VWF ELISA试剂盒) multimers, which are packaged, stored and further processed after secretion. Here, all these processes are being reviewed in detail including background information on the occurring biochemical reactions. [review]
The FVIII C1 domain contributes significantly to the immune response against FVIII in acquired and congenital hemophilia inhibitor patients.
the existing epidemiologic investigations with an overview of the range of possible biochemical and immunologic mechanisms that may contribute to the different immune outcomes observed with plasma-derived and recombinant FVIII products.
It was concluded that VEGF and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.
thrombin (显示 F2 ELISA试剂盒) stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII (显示 UGDH ELISA试剂盒) and by receptor-mediated up-regulation of factor XIII (显示 UGDH ELISA试剂盒) synthesis
cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant
Factor VIIIc is responsible for tissue invasion during tumor progression.
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
, procoagulant component
, antihemophilic factor
, coagulation factor VIII
, coagulation factor VIIIc
, factor VIII F8B
, coagulation factor VIII, procoagulant component (hemophilia A)
, factor VIII
, coagulation co-factor